(140 days)
Not Found
No
The summary describes a mechanical needle-free connector and its performance testing based on established standards and internal methods. There is no mention of AI, ML, image processing, or data training/testing sets, which are typical indicators of AI/ML technology.
No
This device is a connector used for injections and infusions, acting as an accessory to administration sets. It does not directly provide therapy or treatment to the patient.
No
This device is a needle-free connector for administering infusions or taking samples, primarily designed for safety and convenience, not for diagnostic purposes.
No
The device description clearly indicates it is a physical, sterile, non-pyrogenic bidirectional needleless injection valve, which is a hardware component. The performance studies also focus on physical and biological testing of this hardware.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use/Indications for Use: The intended use describes the device as a valve for injections, infusions, and sample taking via intravenous or arterial lines. This is a direct interaction with the patient's circulatory system for administering substances or collecting samples, not for testing those samples in vitro (outside the body).
- Device Description: The description reinforces the intended use, highlighting its function as a needleless injection valve for administering and sampling directly from the patient.
- Lack of IVD Characteristics: There is no mention of the device being used to analyze or test biological samples in vitro. IVDs are typically used to examine blood, urine, tissue, or other specimens to diagnose, monitor, or screen for diseases or conditions.
The device is clearly intended for direct patient care and interaction with the circulatory system, which falls outside the scope of In Vitro Diagnostics.
N/A
Intended Use / Indications for Use
Carefusion NeutraClear™ Needle-free Connector is a bidirectional valve allowing injections and infusions to be given or sample taken via an intravenous line; or samples taken via arterial line. It seals and protects the line when it is not activated. The NeutraClear™ needle-free connector may be used with low-pressure power injectors procedures to a maximum pressure of 325psi with a flow at 10mL per second
Product codes
FPA
Device Description
Carefusion NeutraClear™ Needle-free connector is a sterile, non-pyrogenic bidirectional needleless injection valve intended for single patient use as an accessory to intravascular administration sets allowing infusions to be given or samples taken via an intravenous line or via arterial line without using a needle, thus eliminating the potential for needle-stick injuries during use. It seals and protects the line when it is not activated. This bidirectional needleless injection valve may be used with low-pressure power injectors to a maximum pressure of 325psi with a flow at 10mL per second. The Carefusion NeutraClear™ can be used for up to 200 activations or 7 days.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
intravenous line; arterial line
Indicated Patient Age Range
Not Found
Intended User / Care Setting
General Hospital
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
The following FDA recognized performance standards and guidance were performed in evaluating the functionality of Carefusion NeutraClear™ needle-free connector EL-NC1000:
- ISO 8536-4:2013 Infusion equipment for medical use- Part 4: Infusion sets for single use, gravity feed
- ISO594-2:1998 Conical fittings with 6%(luer) taper for syringes, needles, and certain other medical equipment - part 2 Locking fittings
- ISO8536-10:2015 applies to sterilized infusion sets for single use for use with pressure infusion equipment up to maximum of 200kPa (2 bar)
- ISO14971:2013 Medical devices- Quality management systems- Requirements for regulatory purposes
- ISO 10993-1:2010, Biological evaluation of medical devices - part 1: Evaluation and testing within a risk management process
- ISO 11135:2007 : "Sterilization of Healthcare Products - Ethylene Oxide" : validation of the sterilization process with ethylene oxide according to the half-cycle method
- ISO 11607 Packaging for terminally sterilized medical devices -- Part 1: Requirements for materials, sterile barrier systems and packaging systems -- Part2: Validation requirements for forming, sealing and assembly processes
- ISO 10993-4 Hemolysis Testing: Biological Evaluation of Medical Devices-Part 4 Selection of tests for interactions with blood
The following additional functional performance testing has been carried out to demonstrate that the device performs as intended based on internal specification and test methods:
- Liquid leak-open/closed position (Internal Test Method)
- Vacuum leak- open/closed position (Internal Test Method)
- Microbial Ingress testing
- Pressure Resistance Testing (Internal Test Method)
- Flushing Volume (Internal Test Method)
- Compatibility with Chlorhexidine (Internal Test Method)
Key results: The device met the acceptance criteria for all functional, microbial ingress, sterility, biocompatibility and other performance criteria, which verify it to be substantially equivalent to the predicate device.
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 880.5440 Intravascular administration set.
(a)
Identification. An intravascular administration set is a device used to administer fluids from a container to a patient's vascular system through a needle or catheter inserted into a vein. The device may include the needle or catheter, tubing, a flow regulator, a drip chamber, an infusion line filter, an I.V. set stopcock, fluid delivery tubing, connectors between parts of the set, a side tube with a cap to serve as an injection site, and a hollow spike to penetrate and connect the tubing to an I.V. bag or other infusion fluid container.(b)
Classification. Class II (special controls). The special control for pharmacy compounding systems within this classification is the FDA guidance document entitled “Class II Special Controls Guidance Document: Pharmacy Compounding Systems; Final Guidance for Industry and FDA Reviewers.” Pharmacy compounding systems classified within the intravascular administration set are exempt from the premarket notification procedures in subpart E of this part and subject to the limitations in § 880.9.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized caduceus symbol, which features three human profiles facing right, with a snake-like form intertwined. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the symbol.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
September 1, 2017
Cair L.G.L Delphine Molinari Official Correspondent 1, Allée des Chevreuils Parc Tertiaire de Bois Dieu 69380 Lissieu FRANCE
Re: K171117
Trade/Device Name: Carefusion NeutraClear™ Needle-free connector (EL-NC1000) Regulation Number: 21 CFR 880.5440 Regulation Name: Intravascular Administration Set Regulatory Class: Class II Product Code: FPA Dated: August 7, 2017 Received: August 21, 2017
Dear Ms. Molinari:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in
1
the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely,
Tara A. Ryan -S
for
Lori A. Wiggins, MPT, CLT Acting Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control, and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
510(k) Number (if known) K171117
Device Name
Carefusion NeutraClear™ Needle-free Connector
Indications for Use (Describe)
Carefusion NeutraClear™ Needle-free Connector is a bidirectional valve allowing injections and infusions to be given or sample taken via an intravenous line; or samples taken via arterial line. It seals and protects the line when it is not activated. The NeutraClear™ needle-free connector may be used with low-pressure power injectors procedures to a maximum pressure of 325psi with a flow at 10mL per second
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ------------------------------------------------- | -- |
X Prescription Use (Part 21 CFR 801 Subpart D)
| Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Druq Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
Image /page/3/Picture/0 description: The image shows a logo for CAIR L.G.L. The logo is purple and features a stylized figure with a circle above it, all enclosed within a larger circle. The text "CAIR L.G.L." is written in a stylized font to the right of the figure.
510k Summary
I. Submitter's Identification
Submitter Name: Cair L.G.L Address : 1, Allée des Chevreuils, Parc Tertiaire de Bois Dieu- 69380 Lissieu, France Contact Person: Delphine Molinari Telephone number: +33-0-478-437-744 Fax Number: +33-0-478-437-707 E-mail: dmolinari@cairlgl.fr Date of Preparation: August 29, 2017
II. Identification of the device
Subject Device
Trade Name: Carefusion NeutraClear™ needle-free connector (EL-NC1000) Common Name: Bidirectional needleless injection valve Regulation Name: Intravascular administration set Product Code: FPA Regulation: 21 CFR 880.5440 Device Class: II 510k Number: K171117
Predicate Device
Trade name: NeutraClear TM (EL200 transparent variance) Common Name: Bidirectional needleless injection valve Classification Name: Intravascular administration set Product Code: FPA Regulation: 21 CFR 880.5440 Device Class: II 510k Number: K133073
Page 1 of 6 510k Summary
4
Image /page/4/Picture/0 description: The image shows a logo for CAIR L.G.L. The logo is purple and features a circle with a dot above a triangle. The text "CAIR L.G.L." is to the right of the circle and triangle. The logo is simple and modern.
III. Device Description
Carefusion NeutraClear™ Needle-free connector is a sterile, non-pyrogenic bidirectional needleless injection valve intended for single patient use as an accessory to intravascular administration sets allowing infusions to be given or samples taken via an intravenous line or via arterial line without using a needle, thus eliminating the potential for needle-stick injuries during use. It seals and protects the line when it is not activated. This bidirectional needleless injection valve may be used with low-pressure power injectors to a maximum pressure of 325psi with a flow at 10mL per second. The Carefusion NeutraClear™ can be used for up to 200 activations or 7 days.
IV. Indication for Use
Carefusion NeutraClear™ Needle-free connector is a bidirectional valve allowing injections and infusions to be given or sample taken via an intravenous line; or samples taken via arterial line. It seals and protects the line when it is not activated. The Carefusion NeutraClear™ needle-free connector may be used with low-pressure power injectors procedures to a maximum pressure of 325psi with a flow at 10mL per second.
V. Technological Characteristics
The subject device, Carefusion NeutraClear™ Needle free connector and predicate device, NeutraClear EL200 are both bidirectional needleless injection valves for administration or withdrawal of fluids from a patient through a cannula placed in the vein or for withdraw of blood through the artery. The subject device may be used with low-pressure injectors with a maximum pressure of 325 psi and a flow rate of 10ml per second.
5
Image /page/5/Picture/0 description: The image shows a logo for CAIR L.G.L. The logo is purple and consists of a circle with a line extending from the center to the right, forming a stylized letter 'C'. There is also a purple dot above the circle. The text "CAIR L.G.L." is written in purple to the right of the circle.
Please see below for a comparison table of the Carefusion NeutraClear™ Needle free connector to the predicate device.
| Subject Device | Predicate Device | ||
|---|---|---|---|
| Technological | |||
| Characteristics | Carefusion NeutraClear | ||
| TM Needle-free connector | |||
| EL-NC1000 | NeutraClear EL200 | Substantial | |
| Equivalence | |||
| Product | |||
| Description | Bidirectional needleless | ||
| valve with a permeable | |||
| protective cap in | |||
| Polyethylene | Bidirectional needleless | ||
| valve without a protective | |||
| cap | Different | ||
| Indications for | |||
| Use | Carefusion NeutraClear™ | ||
| Needle-free connector is a | |||
| bidirectional valve allowing | |||
| injections and infusions to | |||
| be given or sample taken | |||
| via an intravenous line; or | |||
| samples taken via arterial | |||
| line. It seals and protects | |||
| the line when it is not | |||
| activated. The Carefusion | |||
| NeutraClear™ needle-free | |||
| connector may be used with | |||
| low-pressure power | |||
| injectors procedures to a | |||
| maximum pressure of | |||
| 325psi with a flow at 10mL | |||
| per second. | NeutraClear™ | ||
| bidirectional needleless | |||
| injection valve is a single | |||
| use, sterile, non-pyrogenic | |||
| device intended for use as | |||
| an accessory to | |||
| intravascular | |||
| administration sets for the | |||
| administration or | |||
| withdrawal of fluids from | |||
| a patient through a | |||
| cannula placed in the vein | |||
| or for withdraw of fluids | |||
| through the artery. | |||
| Bidirectional needleless | |||
| injection valve may be | |||
| used with low-pressure | |||
| power injectors with a | |||
| flow at 10ml/s, in state of | |||
| connection. | Different | ||
| Material | Housing: Polycarbonate | ||
| Seal: Silicone | |||
| Ring: Polyoxymethylene | |||
| Lubricant: Silicone | Housing: Polycarbonate | ||
| Seal: Silicone | |||
| Ring: Polyoxymethylene | |||
| Lubricant: Silicone | Equivalent | ||
| Material of | |||
| protective cap | Polyethylene | N/A | Different |
| Single-use | Yes | Yes | Equivalent |
| Sterilization | |||
| method | Ethylene oxide | Ethylene oxide | Equivalent |
| Shelf life | 3 years | 3 years | Equivalent |
| Environmental | |||
| of Use | General Hospital | General Hospital | Equivalent |
6
Image /page/6/Picture/0 description: The image shows a logo with a purple color scheme. The logo features a circle with a smaller circle above it, connected by a shape that resembles a stylized bird or airplane wing. To the right of the logo is the text "CAIR L.G.L.", also in purple. The logo appears to be for an organization or company with the initials CAIR L.G.L.
| Subject Device | Predicate Device | ||||
|---|---|---|---|---|---|
| Technological | |||||
| Characteristics | Carefusion NeutraClearTM Needle-free connector | ||||
| EL-NC1000 | NeutraClear EL200 | Substantial | |||
| Equivalence | |||||
| Technology and | |||||
| design | When activated by a male | ||||
| Luer, a pre slit elastomeric | |||||
| sleeve advances over an | |||||
| internal post, opening a | |||||
| fluid pathway that connects | |||||
| the female and male ends of | |||||
| the device. | When activated by a male | ||||
| Luer, a pre slit | |||||
| elastomeric sleeve | |||||
| advances over an internal | |||||
| post, opening a fluid | |||||
| pathway that connects the | |||||
| female and male ends of | |||||
| the device. | Equivalent | ||||
| Compatibility | |||||
| with | |||||
| Chlorhexidine | Yes | No | Different | ||
| Flush Volume | 2.5 ml | 10 ml | Different | ||
| Maximum | |||||
| injection | |||||
| pressure | 325psi | 7 bars | Different | ||
| Priming Volume | |||||
| (Dead Volume) | 0.049ml | 0.05ml | Equivalent | ||
| Duration of use | 7 days | ||||
| 200 activations | 7 days | ||||
| 400 activations | Different |
Explanation of Similarities and Differences Technological Characteristics compared to Predicate Device
The Subject device, Carefusion NeutraClear™ Needle-free connector have the following similarities to the predicate device:
- Principle of operation
- Same technology and design ●
- Same configuration
- Same materials used
- Same sterilization method
- Same performance specifications
The following are technical characteristics differences between the subject and predicate devices.
These additional characteristics are verified and validated by testing to demonstrate the subject device is sufficient for its intended use and therefore substantially equivalent to the
7
Image /page/7/Picture/0 description: The image shows a logo with a purple color scheme. The logo features a stylized figure with a pointed head, resembling a person in motion, positioned within a circle. Above the figure is a solid purple circle. To the right of the figure, the text "CAIR L.G.L." is written in a simple, sans-serif font, also in purple.
predicate device. The additional characteristics do not raise different questions of safety or effectiveness.
- . A permeable protective cap is added to the predicate device. The cap is made of Polyethylene and will not contact the fluid path of the device.
- Compatibility with Chlorhexidine
- Increase maximum injection pressure rate to 325 psi for use with power injector ●
- Flush Volume: clears fluid path with 2.5ml of saline ●
- Duration for Use up to 7 days or 200 activations ●
- New Indication for Use introduced to the subject device for using with a low-● pressure power injectors procedures to a maximum pressure of 325 psi with a flow at 10 ml per second.
VI. Performance Data
The following FDA recognized performance standards and guidance were performed in evaluating the functionality of Carefusion NeutraClear™ needle-free connector EL-NC1000:
- ISO 8536-4:2013 Infusion equipment for medical use- Part 4: Infusion sets for single use, gravity feed
- . ISO594-2:1998 Conical fittings with 6%(luer) taper for syringes, needles, and certain other medical equipment - part 2 Locking fittings
- . ISO8536-10:2015 applies to sterilized infusion sets for single use for use with pressure infusion equipment up to maximum of 200kPa (2 bar)
- ISO14971:2013 Medical devices- Quality management systems- Requirements for regulatory purposes
- . ISO 10993-1:2010, Biological evaluation of medical devices - part 1: Evaluation and testing within a risk management process
- ISO 11135:2007 : "Sterilization of Healthcare Products - Ethylene Oxide" : validation of the sterilization process with ethylene oxide according to the half-cycle method
- . ISO 11607 Packaging for terminally sterilized medical devices -- Part 1: Requirements for materials, sterile barrier systems and packaging systems -- Part2: Validation requirements for forming, sealing and assembly processes
- ISO 10993-4 Hemolysis Testing: Biological Evaluation of Medical Devices-Part 4 Selection of tests for interactions with blood
The following additional functional performance testing has been carried out to demonstrate that the device performs as intended based on internal specification and test methods.
8
Image /page/8/Picture/0 description: The image shows a logo for CAIR L.G.L. The logo consists of a circle with a dot above it and a triangle inside it. The text "CAIR L.G.L." is written to the right of the logo.
- Liquid leak-open/closed position (Internal Test Method) ●
- Vacuum leak- open/closed position (Internal Test Method)
- . Microbial Ingress testing
- Pressure Resistance Testing (Internal Test Method)
- Flushing Volume (Internal Test Method)
- Compatibility with Chlorhexidine (Internal Test Method)
VII. Conclusions
The results of the non-clinical testing and risk analysis assessment exhibited that no new questions of safety and efficacy are raised with the proposed introduction of Carefusion NeutraClear™ EL-NC1000. The device met the acceptance criteria for all functional, microbial ingress, sterility, biocompatibility and other performance criteria, which verify it to be substantially equivalent to the predicate device.